Godefridus Johannes Peters - Curriculum Vitae#

(Updated April 2023)

Prof. Dr. Godefridus J. (Frits) Peters, Emeritus professor at Amsterdam University Medical Centers (AUMC), location VU University Medical Center (VUMC) Institute 1: Emeritus and visiting professor at Laboratory Medical Oncology Department Medical Oncology, Amsterdam University Medical Centers.

Institute 2: Full Professor at Department of Biochemistry (since 2019/8), Medical University of Gdańsk.

Main Degrees and Honors

• 1973 Bachelor in biology and chemistry, Faculty of Sciences, University of Nijmegen
  
• 1977 "Graduation" in biology (M.Sc. with pleasure), specialization biochemistry, University of Nijmegen
  
• 1982 Ph.D. thesis at the Faculty of Medicine of the University of Nijmegen (June 4, 1982; Promotor; Prof. Dr. J.H. Veerkamp)
  Thesis: Purine and pyrimidine metabolism in lymphoid cells of man and some other mammalian species
  
• 1982 - 1983 Post-doc at the Netherlands Cancer Institute, Amsterdam
  (Dutch Cancer Society; AUKC 80-3)
  
• 1983 - 1987 Post-Doc and the VU University, Amsterdam
  (Dutch Cancer Society; IKA 83-16)
  
• 1987 - 1992 Senior research fellowship of "Royal Netherlands Academy of Arts and Scien-ces" (KNAW)
  
• 1989 - 1998 Head of the division "Biochemical Pharmacology of the Department of Medical Oncology of the University Hospital VU
  
• 1992 Appointment as "Universitair Hoofddocent" (associate-professor) at the Medical Faculty of the Vrije Universiteit.
  
• 1998 - 2018 Head of the division "Pharmacology" of the Dept. of Medical Oncology of the University Hospital VU.
  
• 1998 - 2003 Deputy Head Clinical Research Laboratory of the Dept. Medical Oncology
  
• 2002 - 2013 Chair of the examination committee of the Master’s in Oncology of the VU University Medical Center
  
• 2003 - 2008 Head Clinical Research Laboratory of the Dept. Medical Oncology of the VU University Medical Center (February 1, 2003)
  
• 2003 Appointed as full professor (June 1, 2003) in Pharmacology of Cytostatics
  
• 2004 - 2017 Member of the Steering Committee of the “VUmc Institute for Cancer and Immunology” (V-ICI); Program Innovative Therapies
  
• 2008 - 2017 Head Laboratory Medical Oncology, which became a separate organizational entity (August 2008), although still affiliated with and part of the Department of Medical Oncology
  
• 2017 Resigned as head Laboratory Medical Oncology
  
• 2017 Staff member of Laboratory Medical Oncology
  
• 2018/5 Emeritus-professor; part-time staff member Laboratory Medical Oncology
  
• 2018-2021Staff member of Laboratory Medical Oncology, Amsterdam University Medical Centers, Location VUMC
  
• 2019/8 Full Professor at the Dept. Biochemistry, Medical University of Gdansk, Gdansk, Poland
  
• 2021/4 Emeritus-professor at the VU University Medical Center, Amsterdam

Awards:

• Eminent Scientist of the year 2007 (Europe) in “Genes and Pharmacogenomics”; awarded by the World Scientists Forum International Awards from the International Research Promotion Council (IRPC).
  
• Featured on the front page of International Journal of Oncology (January 2008)
  
• Featured in several Who is Who editions
  
• Recipient (or co-recipient) of various poster awards.
  
• Burger-Kelland award lecture of the EORTC-PAMM group, Verona, Italy, February 2019.
  
• Full member of the World Academy of Sciences (2020)
  
• Honorary Advisor of the Universal Scientific Education and Research Network (USERN).(2021-)
  
• Honorary Professor at Amity University, Noida, India (2023)
  
• Anne Simmonds Award lecture at PP23, the biennual meeting of the Purine and Pyrimidine Society (PPS) on metabolism as a targets for drug development.
  
• 2023: no 9 of Top Polish Scientists in the field of Medicine according to Research.com (D-index; Discipline H-index 86
  

Acquired funding:

• KNAW fellowship (1987 - 1992)
  
• Dutch Cancer Society (11 grants since 1988)
  
• European Cancer Center-fellowship (1993 - 1994)
  
• Platform Alternatieven Dierproeven (“Alternatives for Animal experimentation”) (1993 - 1997)
  
• European Union Biomed II shared cost grant on deoxynucleoside kinases (1996 - 1999)
  
• European Union grant for outermost regions in collaboration with the University of La Laguna (CIBICAN; 2010 - 2015)
  
• NWO AGIKO grant for R. Mauritz (2001 - 2005)
  
• NWO-sponsor of visiting professorship for Prof. Dr. Y.G. Assaraf (Haifa, Israel) (2009 - 2010)
  
• KNAW-sponsor of visiting professorship for Prof. Dr. Y.G. Assaraf (Haifa, Israel)
  
• NWO sponsor of visiting professorship of Dr. O. Firuzi, Iran ((2017)
  
• Fundacao para a Ciencia e a Tecnologia (Ministry of Science, Portugal) for C. De Lemos (2005 - 2008)
  
• Cancer Center Amsterdam (co-supervisor with E. Giovannetti) for one Ph.D. student (2012 - 2016)
  
• Cancer Center Amsterdam (co-supervisor with G. Jansen) for one technician (2012 - 2014)
  
• Several Marie Curie grants (2008: E. Giovannetti; 2012: E. Galvani)
  
• OPUS grant, National Science Center, Poland (2019 - 2023)
  
• Total amount of non-profit funding: until 2001: HFL 8.1 million; after 2001: EUR 3.5 million
• Several industrial grants [Agouron (now Pfizer), AstraZeneca Ltd, Aventis Pharma (now Sanofi-Aventis), Bristol-Myers, Burrough-Welcome (now Glaxo-Smith-Kline), Clavis Pharmaceuticals (previously part of Norsk-Hydro) (various grants), Cyanamide-Lederle, Dupont-de Nemours, Eli Lilly & Co (various grants), EORTC groups, GPC-Biotech, Heidelberg Pharma, Klinge-Pharma (now Fujisawa), Parke-Davis (now Pfizer), Rexahn Pharmaceuticals/Teva Pharma, Roche Pharmaceuticals (various grants), Schering-Plough, Shire Pharmaceuticals, Sparta Pharmaceuticals, Spectrum Pharmaceuticals, Sugen (now Pfizer), Taiho Pharmaceuticals (several grants), Transave, US Biosciences, Welstat.
  Total amount: Until 2001; HFL 1.7 million; after 2001: EUR: 3.6 million

Post-academic experience

• Aug 1977 - Jun 1982 Dept. Biochemistry, Faculty of Medicine, University of Nijmegen (Supervisor: Prof. Dr. J.H. Veerkamp)
  
• Sep 1980 - Nov 1980 On leave to Edmonton, Canada (Dr. J.F. Henderson); Calgary, Canada (Dr. F. Snyder); San Diego (Prof. Dr.J.E. Seegmiller)
  
• Jul 1982 - Mar 1983 Dept. Biochemistry, Netherlands Cancer Institute, Amsterdam (Supervisor: Prof. Dr. H.M. Pinedo)
  
• Apr 1983 - April 2021 Department of Medical Oncology, University Hospital VU, now VU University Medical Center (Until 2002: Head: Prof. Dr. H.M. Pinedo; 2003-2007: Head: Prof. Dr. G. Giaccone; 2008-2019: Head: Prof. Dr. H.M.W. Verheul; 2019-, Mrs. Prof. Dr. H.W.M. van Laarhoven)
  
• Sept 2019 - present Guest professor at the Department of Biochemistry, Medical University of Gdansk, Poland (Head: Prof. Dr. RT Smolenski)
  
• April 2021 - present Emeritus and visiting professor at the Amsterdam UMC, location VUMC

Relevant national-international memberships

Societies

• Society of research-fellows of the Royal Netherlands Academy of Sciences (KNAW)
  
• Member of the council (April 1990 - October 1993)
  
• Secretary (October 1990 - April 1993)
  
• Member "Werkgroep Dierproeven in Kankeronderzoek": establishment of a "Code of practice" for animal experimentation. (1998 - 1999)
  
• American Association for Cancer Research (1987)
  
• Member of several committees such as Drug Resistance and the Centennial grant
  
• European Organization for Research and treatment of Cancer (EORTC)
  
• Member of the General Assembly (2009-2015)
  
• Pharmacology and Molecular Mechanisms Group (PAMM) (1984)
  
  • Member of the Council (June 1991)
    
  • Chair-elect (2007 - 2009)
    
  • Chair (2009 - 2015)
    
  • Secretary (2015 - 2018)
    
  • Screening and Pharmacology Group (SPG) (1997 - 2003), merged with PAMM in 2003
    
• Drug Discovery Committee (DDC; successor of SPG) (2003)
  
  • Chair of the Drug Discovery Committee (DDC) (2007 - 2010; 2014 - 2017)
    
• Member of the Translational Research Advisory Committee (TRAC) (2008)
  
• International Society on Nucleosides, Nucleotides and Nucleic Acids (IS3NA) (2001)
  
• European Society for the Study on Purine and Pyrimidine Metabolism (ESSPPMM) (1987 - 2006)
  
  • Member of the council (September 1995 - 2006)
    
  • Member of the executive committee (1999 - 2006)
    
  • Vice-president (1999 - 2001)
    
  • President (2001-2004) (Co-founder of PPS)
    
• Purine and Pyrimidine Society (PPS) (successor of the ESSPPMM)
  
  • Member of the council (2006)
    
  • Publication secretary (2008)
    
  • Secretary (2011 - 2017)
    
  • Treasurer (2017)
    
• Purine and Pyrimidine Foundation
  
  • Secretary/Treasurer (2012-)
    
• Folate receptor Society (2010-)
  
  • Treasurer (2018-)
    
• Folate receptor Foundation (2014-)
  
  • Treasurer (2014-)
    
• International Association of Physical Chemists (IAPC)
  
  • Vice-president (2021-)

Scientific Committees

• “International Symposia on Purine and Pyrimidine Metabolism in Man" (PPMM)
  
  • PP91, Bournemouth, England, (joint with ESSPPMM) June 1991,
    
  • PP94, Bloomington, IN, USA, June 1994,
    
  • PP97, Gmunden, Austria (joint with ESSPPMM), June 1997
    
  • PP00, Tel Aviv, Israel, May 2000
    
  • PP03, Egmond aan Zee, the Netherlands (joint with ESSPPMM) (Chair), June 2003
    
  • PP07, Chicago, MI, USA, June 2007
    
  • PP09, Stockholm, Sweden, June 2009
    
  • PP11, Tokyo, Japan, February 2011
    
  • PP13, Madrid, Spain, June 2013
    
  • PP15, New York, NY, USA, June 2015
    
  • PP17, Gdansk, Poland, September 2017
    
  • PP19, Lyon, France, June 2019
    
  • PP21, online meeting of the PPS, June 2021
    
  • PP23, Los Angeles, CA, June 2023)
    
• European Society for the Study on Purine and Pyrimidine Metabolism in Man (ESSPPMM)
  
  • ESSPPMM'93, Nijmegen, Netherlands, September, 1993; vice-president
    
  • ESSPPMM’95; Vasto, Italy, September 1995
    
  • ESSPPMM’99, Gdansk, Poland, September 1999
    
  • ESSPPMM’01, Bruges, Belgium, September 2001
    
  • ESSPPMM’05, Prague, Czech Republic, June 2005
    
• "European Society of Medical Oncology (ESMO)", Lyon, France, 1992.
  
• European Organization for Research and Treatment of Cancer (EORTC)
  
• Pharmacology and Molecular Mechanism (PAMM) group meetings:
  
  • Winter EORTC-PAMM meeting, Toulouse, France, January 1995
    
  • Winter EORTC-PAMM meeting, Amsterdam, the Netherlands, 1999, co-chair
    
  • Winter EORTC-PAMM meeting, Florence, Italy, January 2003.
    
  • Winter EORTC-PAMM meeting, Edinburgh, Scotland, January 2006
    
  • Winter EORTC-PAMM meeting, Palermo, Italy, January 2008
    
  • Winter EORTC-PAMM meeting, Brussels, Belgium, March 2009, chair
    
  • Winter EORTC-PAMM meeting, Toulouse, France, January 2010.
    
  • Winter EORTC-PAMM meeting, Gdansk, Poland, January 2011.
    
  • Winter EORTC-PAMM meeting, Puerto de la Cruz, Tenerife, Spain, January 2012
    
  • Winter EORTC-PAMM meeting, Cardiff, Wales, UK, January 2013
    
  • Winter EORTC-PAMM meeting, Münster, Germany, February 2014
    
  • Winter EORTC-PAMM meeting, Marseille, France, January 2015
    
  • Winter EORTC-PAMM meeting, Antwerp, Belgium, February 2016
    
  • Winter EORTC-PAMM meeting, Split, Croatia, March 2017; co-chair
    
  • Winter EORTC-PAMM meeting, Rom, Italy, February 2018, co-chair
    
  • Winter EORTC-PAMM meeting, Verona, Italy, February 2019
    
• Educational course on Methodology in Pharmacological Research, co-chair
  
  • Winter EORTC-PAMM meeting, Stockholm, Sweden, February 2020
    
  • Winter-Spring EORTC-PAMM, online meeting, April 2021
    
  • Winter EORTC-PAMM-meeting, Florence, Italy, December 2022
    
• “NCI-EORTC meetings on drug development”: Abstract review committee, 1996, 1998, 2000.
  
• 24th EORTC-NCI-AACR meeting on drug development; Dublin, Ireland; November 2012; Member of the Scientific Committee
  
• 25th EORTC-NCI-AACR meeting on drug development; Boston, MA, USA, November 2013; Member of the Scientific Committee
  
• 26th EORTC-NCI-AACR meeting on drug development; Barcelona, Spain, November 2014; Member of the Scientific Committee
  
• "Drug resistance in Leukemia and Lymphoma", Amsterdam, 1998, 2003
  
• Member of the Scientific Committee of the 5th International Symposium on "Drug resistance in Leukemia and Lymphoma", Amsterdam, March 2003
  
• Scientific Committee of International Meeting on Chemotherapy of Cancer, Florence, Italy, 2003.
  
• AACR Drug Resistance Committee, AACR meeting, Los Angeles, 2007.
  
• Scientific committee of the 14th International Symposium on Chemistry and Biology of Pteridines and Folates, Jeju Island, South Korea, 2009
  
• Scientific committee of the 15th International Symposium on Chemistry and Biology of Pteridines and Folates, Antalya, Turkey, May 2012
  
• EACR-meeting on Drug Development, chairman scientific committee, Antalya, Turkey, 2011.
  
• IAPC-8 Meeting: 8th World conference on physico-chemical methods in drug discovery and development and 4th World conference on ADMET and DMPK: Split, Croatia (September 2019)
  
• IAPC-10 Meeting: Joint World Conferences on Physico Chemical Methods in Drug Discovery and Development and on ADMET and DMPK, Belgrade, Serbia, September 04-06, 2023

Organizing committee of scientific meetings

• ESSPPMM'93: Co-organizer (vice-president). September, 1993, Nijmegen, Netherlands
  
• "Colorectal Cancer: from Gene to Cure": Co-organizer. Amsterdam, 1995
  
• "Pancreatic Cancer: from Gene to Cure": Co-organizer. Amsterdam, 1999
  
• PAMMsterdam 99, the winter meeting of the EORTC-PAMM group: Co-Organizer. Amsterdam, the Netherlands, 1999
  
• “Chemotherapeutic approaches of colorectal cancer": Co-President of the organizing committee and President of the Scientific Committee. Amsterdam, February 1999.
  
• "Cancer of the Esophagus and gastric cardia: from Gene to Cure": Co-organizer. Amsterdam, 2002
  
• Joint meeting of the ESPPMM and International Symposium on Purine and Pyrimidine Metabolism in Man: Organizer. Egmond aan Zee, the Netherlands, 2003.
  
• 13th International Symposium on Chemistry and Biology of Pteridines and Folates: Co-chair. Amsterdam/Egmond aan Zee, the Netherlands, 2005.
  
• PAMM09, the pre-EGAM EORTC-PAMM meeting: Organizer. Brussels, Belgium, March 2009.
  
• The 5th biennial meeting of the Folate Receptor Society. Co-organizer, Amsterdam, September-October 2014
  
• CIBICAN Conference on Molecular Pharmacology and Mechanisms of New Anticancer Drugs, joint with Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells, COST Action CM1106; Puerto de la Cruz, Tenerife, October 14-15, 2014
  
• The 7th biennial meeting of the Folate Receptor Society. Co-organizer (treasurer), Taormina, Sicily, Italy, September-October 2018
  
• The 8th International Symposium on Folate Biology and Therapeutics”, Briarcliff Manor, NJ, USA,October 2023 organized by the Folate Receptor Society. Co-organizer (treasurer)

Scientific advisory boards - member

• “Cancéropôle Lyon-Auvergne-Rhône-Alpes”, Lyon, France (2004 - 2009)
  
• Clavis Pharma, Oslo, Norway (1999 - 2014)
  
• Clear Creek Pharma, Boston, MA, USA (2017 - )
  
• Ellipses Pharma, London, UK (2017 - )
  
• Heidelberg Pharma GmbH, Ladenburg, Germany (1999 - 2005)
  
• Isofol-Medical AB, Göteborg, Sweden (2020-)
  
• Kucera Pharmaceutical, Winston-Salem, NC, USA (2008 - 2014)
  
• Rexahn Pharmaceutical, Rockville, MD, USA (2014 - 2020)
  
• Salzburg Therapeutics, Winston-Salem, NC, USA (2008 -)
  
• Taiho Pharmaceuticals, Tokyo, Japan (2013 - 2020)

Grant Review Committees

• CAIXA; ”la Caixa” Banking Foundation – Area of Research and Strategy (2019, 2020)
  
• Agency for health Quality and Assessment of Catalonia (Cahta Research)
  
• Panel member La Marato de TV3 call on Cancer (2009, 2013, 2019)
  
• INSERM, Paris, France
  
• Grant reviews
  
  • Thematic Research and Healthcare Centers (TRHCs)
    
  • Research Foundation Flanders (FWO)
    
  • Panel member Med4; Cancer (2013-2019)
    
  • Panel member “Sta op tegen kanker” (Stand-up to cancer); 2018, 2019, 2021, 2022
    
• Review Committee UICC for TCRF and ACSBI grants (1998-2014)
  
• Travel grants (ICRETT, technical Fellowships)
  
• Review Committee AACR Pre- and Postdoctoral Centennial Grants (2008)
  
• Review Committee Translational Research, Institute National du Cancer (INCa) 2008-2011
  
• Translational Research in Cancer
  
• Expert Centers for Rare Cancer
  
• Review Committee ‘Agence Nationale de la Recherche’ (ANR), Paris, France (2008-2014)
  
• Programme interdisciplinaire en Physique et chimie du vivant (PCV)
  
• Equipex
  
• PHU (Pôle Hospitalo-Universitaire) Cancer
  
• Innovatie door Wetenschap en Technologie (IWT; Agency for Innovation by Science and Technology), Flanders (2015)
  
• TBM proposals (Applied Biomedical Sciences)
  
• Vice-chairman of the committee for "Wetenschappelijk Onderzoek"
  
• (Scientific Research) of the Graduate School of Oncology (1997-2003)

Grant Review

• AIRC (Associazione Italiana per la Ricerca sul Cancro), Italian Association for Cancer Research, Italy
  
• AGENTSCHAP INNOVEREN & ONDERNEMEN (Belgian agency for innovation and business entrepreneur)
  
• Austrian Science Fund (FWF)
  
• Belgian Foundation against Cancer
  
• Biotechnology and Biological Sciences Research Council (BBSRC).
  
• Cancer Research UK
  
• Grant Reviews
  
• Quinquennial Reviews
  
• Czech Science Foundation
  
• Dutch Cancer Society (Koningin Wilhelmina Fonds)
  
• Italian Ministry of Health (MOH) – Ricerca Finalizzata
  
• National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), UK
  
• National Science Center, Cracow, Poland
  
• Swiss Cancer League
  
• ZonMW (Medical Sciences) and NWO, the Netherlands
  
• Recommendations for personal promotions at various universities (the Netherlands, Belgium, France, England, Germany, USA, Canada, Australia)

Scientific advisory meetings – ad hoc

• Acrotech Biopharma, CA, USA
  
• Adamet, Gdansk, Poland,
  
• Aposense, Haifa, Israel
  
• Astra-Zeneca Ltd, England
  
• Bird & Bird LLP. London, UK
  
• Boehringer Ingelheim, Europe,
  
• Bristol-Myers-Squibb, NJ
  
• Chiron Pharmaceuticals, USA
  
• Clear Creek Bio, Boston, MA, USA
  
• Clovis Oncology, Boulder, CO, USA
  
• Cyanamide-Lederle (after that American Home Products)
  
• Eli Lilly & Co, Indianapolis, IN, USA and Lilly Netherlands
  
• Ellipses, London, UK
  
• Gene Express, Inc, Toledo, OH, USA
  
• Isofol, Gothenburg, Sweden
  
• Kyowa-Hakko Pharmaceuticals, Tokyo, Japan
  
• Nektar Therapeutics, San Francisco, CA, USA
  
• Pfizer Oncology, New York, NY, USA
  
• Processa Pharmaceutical, Hanover, MD, USA
  
• Saladex, Bethlehem, PA, USA
  
• Seagen, USA
  
• Servier, Leiden, the Netherlands
  
• Spectrum Pharmaceuticals, New York, NY, USA
  
• Taiho Pharmaceuticals, Tokyo, Japan,
  
• Taiho Pharmaceuticals USA Inc, New Jersey, USA
  
• Unibioscreen, Belgium
  
• Warner-Lambert-Parke-Davis (now part of Pfizer), Ann Arrbor, Mi, USA
  
• Wellstat Biopharma Inc, Gaithersburg, MD, USA

Editorial boards

• Yearbook of the Society of fellows of the Royal Netherlands Academy of Sciences (1988-1993; co-editor of 4 issues)
  
• The International Journal of Purine and Pyrimidine Research (1989-1992)
  
• Oncology Reports (1995-1998)
  
• European Journal of Cancer (1995-2015)
  
• South-American Journal of Cancer (1998-2003)
  
• Electronic Journal of Oncology (1999-2003)
  
• Clinical Colorectal Cancer (1999-2018)
  
• Cancer Chemotherapy and Pharmacology (2000-)
  
• Guest editor: Contemporary Reviews (2015-)
  
• International Journal of Oncology (2001-)
  
• Cancer Therapy (2003-)
  
• Journal of Chemotherapy (2004-)
  
• Annals of Oncology (2005-2014)
  
• Journal of Pharmacology and Toxicology (2006-)
  
• Journal of Epithelial Biology and Pharmacology (2008-2014)
  
• Gastrointestinal Cancer Review Letters (2008-)
  
• The Open Lung Cancer Journal (2009-2013), editor-in-chief
  
• Chemotherapy Research and Practice (2009-2017)
  
• World Journal of Gastrointestinal Oncology (2009-2018)
  
• World Journal of Gastrointestinal Pharmacology and Therapeutics (2009-2018)
  
• Journal of Chinese Clinical Medicine (2009-)
  
• World Journal of Clinical Oncology (2010-2023), editorial board
  
  • (2010-2015), Strategy Associate Editor-in Chief
    
  • (2015-2018) Editor-in-Chief
    
• American Journal of Cancer research (2010-), senior editor
  
• Chinese Journal of Clinicians (2010-)
  
• World Journal of Pharmacology (2011-)
  
• Nucleosides, Nucleotides and Nucleic Acids (2011-)
  
• Journal of Cancer Therapeutics and Research (2011-), Editor-in Chief
  
• Journal of Solid Tumors (2011-), senior editor
  
• Experimental Hematology and Oncology (2012-)
  
• Pteridines (2012-)
  
• Oncology Discovery (2012-), Editor-in-Chief
  
• Expert Opinion on Drug Metabolism and Toxicology (2013-)
  
• Journal of Tumor (2013-)
  
• Journal of Zhejiang University-SCIENCE B (JZUS-B) (2013-)
  
• Applied Scientific Reports (2013-)
  
• Pharmacology and Alternative Medicine Therapeutics (2014-)
  
• Amino Acids (2014-)
  
• Consulting/section editor (2019-)
  
• Hyperplasia of Cancer (2014-)
  
• Journal of Cancer Metastasis and Treatment (2014-), Associate Editor
  
• Expert Review of Precision Medicine and Drug Development, (2015-)
  
• Heliyon (2016-2019)
  
• Atlas of Genetics, section editor DNA repair (2017-)
  
• ADMET & DMPK (2015-2020), section editor Oncology
  
• Cancer Drug Resistance (2017-), Founder and Editor-in-Chief
  
• International Journal of Molecular Sciences (2019-)
  
• Cancers, (2020-)
  
• Translational; Oncology (2020-)
  
• World Academy of Sciences Journal, Editorial advisor (2020-)
  
• World Journal of Gastroenterology (2020-)
  
• Cancer Diagnosis and Prognosis (2020-)
  
• Current Biomarkers (2021-)
  
• Future Pharmacology (2021-)
  
• Expert Opinion on Pharmacotherapy (2021-)
  
• Pharmacogenomics Research and Personalized Medicine (2021-)
  
• Precision Cancer Medicine (2021-)
  
• Academia Biology, Academic Editor (2022-)
  
• Translational Cancer Research, (2022-)
  
• Frontiers in Pharmacology/Oncology, Pharmacology Anticancer Drugs, Assoc Editor (2022-)

Referee for several other Cancer Journals (Cancer Research, Clinical Cancer research, Molecular Cancer Therapeutics, Journal Cancer Research Clinical Oncology, International Journal of Cancer, etc) and other Journals (Biochemical Pharmacology, Pharmacy World & Science, European Journal of Pharmacology, etc)

Editor of:

1. M.H. Roos, E.L.J.M. van Luytelaer, G.J. Peters (1990).
Van frictie tot wetenschap. Jaarboek 1989; Vereniging van Akademie-Onderzoekers.

2. E.L.J.M. van Luytelaer, G.J. Peters, J.M.M.H. Thijssen, I.F.J. de Jong, M.E. Vogelzang (1991).
Van frictie tot wetenschap. Jaarboek 1990-1991; Vereniging van Akademie-Onderzoekers

3. J.M.M.H. Thijssen, I.F.J. de Jong, G.J. Peters, E.L.J.M. van Luijtelaer (1992).
Van frictie tot wetenschap. Jaarboek 1991-1992; Vereniging van Akademie-Onderzoekers.

4. I.J.F. de Jong, G.J. Peters, J.M.M.H. Thijssen, J. van der Zee (1993).
Van frictie tot wetenschap. Jaarboek 1992-1993; Vereniging van Akademie-Onderzoekers.

5. G.J. Peters (1993)
Abstracts of Papers and Posters of "Fourth Symposium of the European Society for the Study of Purine and Pyrimidine Metabolism in Man", Nijmegen, the Netherlands, 31 August - 3 September 1993 [Pharmacy World & Science 15 (Supplement F); pp. F1-F32, 1993]

6. G.J. Peters & J.H. Beijnen (1994)
Guest Editor Pharmacy World & Science, Vol 16, special issue on "Purine and Pyrimidine Metabolism".

7. G.J. Peters, W. Plunkett (1995)
Guest editors of Seminars of Oncology, with a sup¬plement on the "Gemcitabine Hydrochloride: Status of preclinical studies" (Vol 22; issue 4, suppl 11, pp. 1-82)

8. G.N.J. Tytgat, D.J. Gouma, G.J.A. Offerhaus, G.J. Peters, H.M. Pinedo, G. Bartelink (1999).
Guest editors of Annals of Oncology, with a supplement on "Biliopancreatic malignancy: From gene to cure" (Vol 10; suppl 4).

9. G.J. Peters (1999).
Abstracts of the EORTC-PAMM winter group meeting.

10. G.J. Peters (1999)
Abstracts of the “Chemotherapeutic approaches of colorectal cancer” meeting.

11. G.J. Peters (2003)
Abstracts of PP03, the 9th Joint symposium of the ESSPPMM and 11th International symposium on Purine and Pyrimidine Metabolism

12. G.J. Peters, A.B.P. van Kuilenburg & R.A. de Abreu (2004)

Guest Editors of Nucleosides, Nucleotides and Nucleic Acids (Vol 23; issue 8-9, pp. 1077-1563), a special issue on PP03, the 9th Joint symposium of the ESSPPM¬M and 11th International symposium on Purine and Pyrimidine Metabolism.

13. G.J. Peters & G. Jansen (2005).
Pteridines, (Vol 16; issue 2, pp 41-123). A special issue for the abstracts of the 13th International Symposium on Chemistry and Biology of Pteridines and Folates

14. G.J. Peters (2006).
Deoxynucleoside analogs in Cancer Therapy.
Humana Press, Totowa, NJ, USA, pp. 1-476.

15. G.J. Peters & I. Sebesta (2006)
Guest Editors of Nucleosides, Nucleotides and Nucleic Acids (Vol 25; issue 9-11, pp. 971-1308), a special issue on PP05, the 10th symposium of the ESSPPMM.

16. G. Jansen & G.J. Peters (2007)
Chemistry and Biology of Pteridines and Folates; Proceedings of the 13th International Symposium.. SPS publications, SPS Verlagsgesellschaft, Heilbronn, pp. 1-607.

17. R.A. Sabina, G.J. Peters, M.A. Becker (2008)
Guest Editors of Nucleosides, Nucleotides and Nucleic Acids (Vol 27; issue 6-7, pp. 547-899, 2008) a special issue on PP07, the 12th International Purine and Pyrimidine Symposium.

18. G.J. Peters (2009).
Abstracts of the EORTC-Laboratory Research Division meeting (joint EORTC-Pharmacology and Molecular Mechanisms and EORTC-Pathobiology Group), Brussels, Belgium.

19. F. Muggia, G.J. Peters (2009)
Guest editor of Molecular Cancer Therapeutics (an AACR Journal). A special issue (May 2009) dedicated to the 50th anniversary of 5-fluorouracil and other targeted agents.

20. G.J. Peters, S.A. Eriksson (2010)
Guest Editors of Nucleosides, Nucleotides and Nucleic Acids (Vol 29; issue 4-6, pp. i-xvii and 267-521, 2010) a special issue on PP09, the 13th International Purine and Pyrimidine Symposium

21. G.J. Peters, K. Ichida (2011)
Guest Editors of Nucleosides, Nucleotides and Nucleic Acids (Vol 30; issue 12, pp. 999-1340, 2011), a special issue on PP11, the 14th International Purine and Pyrimidine Symposium.

22. E. Giovannetti G.J. Peters (2013)
Guest editors of a special issue of Current Pharmaceutical Design (Vol. 19; issue 5, pp. 807-964) on “Development of new molecular agents targeting key signalling pathways activated by growth factors in human cancer”.

23. R. Torres, J.G. Puig, G.J. Peters (2014).
Guest Editors of Nucleosides, Nucleotides and Nucleic Acids, a special issue on PP13, the 15th International Purine and Pyrimidine Symposium (Vol 33; issue 4-6, pp. 163-453)

24. M. Hirano, G.J. Peters (2016).
Guest Editors of Nucleosides, Nucleotides and Nucleic Acids, a special issue on PP15, the 16th International Purine and Pyrimidine Symposium (Vol 35; issue 10-12, pp. 495-736)

25. R.T. Smolenski, G.J. Peters (2018)
Guest Editors of Nucleosides, Nucleotides and Nucleic Acids, a special issue on PP17, the 17th International Purine and Pyrimidine Symposium, (vol 37: issues 5-6, 11-12 , pp. 261-360 and 585-723.

26. L.P. Jordheim, S. Peyrottes, G.J. Peters (2020)
Guest Editors of Nucleosides, Nucleotides and Nucleic Acids, a special issue on PP19, the 18th International Purine and Pyrimidine Symposium (Vol. 39; issues 10-12; pp. 1271-1473).

27. S. Peyrottes, G.J. Peters, & L.P. Jordheim (2022)
Guest Editors of Nucleosides, Nucleotides and Nucleic Acids, a special issue on PP21, the online 19th International Purine and Pyrimidine Symposium (Vol 41: issue 3 [pp. 221-284, 314-341], issue 4 [343-369], issue 11 [pp. 1099-1108] and 12; [pp. 1265-1395]

(Co)-promotor of the Ph.D. thesis of:

1. C.J. van Groeningen. (December 19, 1990)
"Clinical Pharmacology and biochemical modulation of 5-fluorouracil. Effects of leucovorin and uridine".
(Promotor: Prof. Dr. H.M. Pinedo; Co-promotor: Dr. G.J. Peters; Referent: Dr. J.H. Schornagel)

2. P.E. Pizao. (December 21, 1992)
"Multilayered post-confluent tumor cell cultures as a model for in vitro chemosensitivity tests"
(Promotor: Prof. Dr. H.M. Pinedo; co-promotors: Dr. G.J. Peters, G. Giaccone, M.D.; Referent: Prof. Dr. L.A. Smets)

3. C.L. van der Wilt. (February 3, 1994)
"Metabolic modulation of 5-fluorouracil activity in colon cancer"
(Promotor: Prof. Dr. H.M. Pinedo; Co-promotor: Dr. G.J. Peters; Referent: Prof. A.H. Calvert [Newcastle-upon-Tyne, England])

4. V.W.T. Ruiz van Haperen. (January 18, 1995)
"Biochemical Pharmacology of 2',2'-difluoro-2'deoxycytid¬ine (Gemcitabine)"
(Promotor: Prof. Dr. H.M. Pinedo; co-promotors: Dr. G.J. Peters, Dr. J.B. Vermorken; Referent: Prof. Dr. W. Plunkett [Houston, Texas, U.S.A.])

5. J.A.M. van Laar. (March 8, 1996)
"Reappraisal of 5-fluoro-2'deoxyuridine in comparison to 5-fluorouracil and modulation by N-phosphon-acetyl-L-aspartate",
(Promotors: Prof. Dr. H.M. Pinedo, Prof. Dr. Y.M. Rustum [Buffalo, NY, USA]; Co-promotor: Dr. G.J. Peters)

6. C.J.A. van Moorsel. (December 9, 1999)
"Preclinical and clinical interactions between gemcitabine and cisplatin in ovarian, non-small cell lung and head and neck cancer"
(Promotors: Prof. Dr. H.M. Pinedo, Prof. Dr. J.B. Vermorken; co-promotors: Dr. G.J. Peters, Prof. Dr. P.E. Postmus).

7. B. van Triest (June 7, 2000)
"Thymidylate synthase as predictive parameter for the antitumor activity of 5-fluorouracil and novel antifolates"
(Promotor: Prof. Dr. H.M. Pinedo; co-promotors: Dr. G.J. Peters, Dr. C.J. van Groeningen)

8. M.G. Rots (September 27, 2000)
"Classification and circumvention of methotrexate resistance in childhood leukemia: a clinically directed laboratory study"
(Promotor: Prof. Dr. A.J.P. Veerman; co-promotors: Prof.Dr. R. Pieters, Dr. G.J. Peters, Dr. G. Jansen).

9. H.H.J. Backus (June 21, 2001)
“Downstream effects of thymidylate synthase inhibition”
(Promotor: Prof. Dr. H.M. Pinedo; co-promotors: Dr. G.J. Peters, Dr. C.J. van Groeningen)

10. A.M. Bergman (June 5, 2002)
“Resistance, cross-resistance and collateral sensitivity to gemcitabine”
Promotor: Prof. Dr. H.M. Pinedo; Co-promotor: Dr. G.J. Peters

11. J.R. Kroep (February 12, 2003).
“Preclinical and clinical pharmacology of gemcitabine & combinations with paclitaxel and cisplatin.”
Promotor: Prof. Dr. H.M. Pinedo; co-promotors: Dr. G.J. Peters, Dr. C.J. van Groeningen)

12. M. de Bruin (November 10, 2004)
“Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in drug sensitivity and angiogenesis”
Promotores: Prof.dr. H.M. Pinedo, Prof. Dr. G.J. Peters. Co-promotor: Dr. K. Hoekman

13. I. Hubeek (November 10, 2005)
“Cytarabine resistance in childhood acute myeloid leukemia”
Promotors: Prof. Dr. A.J.P. Veerman, Prof. Dr. G.J. Peters. Co-promoter: Dr. G.J.L. Kaspers

14. O.H. Temmink (October 3, 2007)
Role of thymidine phosphorylase/platelet derived endothelial cell growth factor inhibition in the cytotoxicity of fluoropyrimidines.
Promotor: Prof. Dr. G.J. Peters. Co-promotor: Dr. M. Fukushima (Japan)

15. C. Lemos (October 10, 2008; Porto, Portugal)
Folate supplementation in chemotherapy: Increase of efficacy versus induction of drug resistance.
Promotors: Prof. Dr. C. Calhau (Porto), Prof. Dr. I. Azevedo (Porto), Prof. Dr. G.J. Peters; co-promotor: Dr. G. Jansen.
Faculdade de Medicina da Universidade de Porto, Portugal.

16. I.V. Bijnsdorp (June 9, 2010)
Dual role of thymidine phosphorylase inhibition: enhancement of cytotoxicity and angiogenesis.
Promotor: Prof. Dr. G.J. Peters; co-promotor: Dr. F.A.E. Kruyt.

17. J.M.G.H. van Riel (September 17, 2010).
Hepatic arterial chemotherapy for liver metastases of colorectal cancer/
Promotoren: Prof. Dr. E. Boven, Prof. Dr. G.J. Peters; co-promotor: Dr. C.J. van Groeningen

18. P. Noordhuis (October 21, 2010).
Molecular aspects of 5-fluorouracil and oxaliplatin activity and resistance.
Promotor: Prof. Dr. G.J. Peters; co-promotor: Dr. C.J. van Groeningen

19. R. Mauritz (February 10, 2011),
Determinants of antifolate therapy in solid tumors.
Promotors: Prof. Dr. G.J. Peters; co-promotor: Dr. G. Jansen

20. G. Codacci-Pisanelli (November 23, 2012)
Biochemical modulation of 5-fluorouracil by uridine and leucovorin.
Promotors: Prof. Dr. G.J. Peters; co-promotors: Dr. C.J. van Groeningen, Dr. C.L. van der Wilt

21. K. Azijli (April 17, 2013; University of Groningen).
Modulation of TRAIL induced apoptosis; role of signaling pathways.
Promotors: Prof. Dr. F.A.E. Kruyt (Groningen), Prof. Dr. S. de Jong (Groningen), Prof. Dr. G.J. Peters

22. M.S.M.A. El-Naggar (August 21, 2013) (University of Assiut, Egypt)
Gemcitabine as radiosensitizer for newly diagnosed high grade glioblastoma.
Promotors: Prof. Dr. S.S.M. Eid (Assiut), Prof. Dr. A.I. Elgeriany (Assiut), Prof. Dr. G.J. Peters; co-promoter: Dr. M.M. Omar (Assiut).

23. A. (Amir) Avan (January 13, 2014)).
Novel therapeutic approaches for pancreatic cancer.
Promotor: Prof. Dr. G.J. Peters; co-promotor: Dr. E. Giovannetti, Dr. T. Würdinger, Dr. G.J. Schuurhuis

24. M. Maftouh (June 11, 2014)
New avenues in pancreatic cancer: targeting epigenetics and metabolism.
Promotor: Prof. Dr. G.J. Peters; co-promotor: Dr. E. Giovannetti

25. A. (Abolfazl) Avan (November 16, 2015)
Pathogenesis of Neurotoxicity and Role of Signaling in the Efficacy of Anticancer Agents
Promotor: Prof. Dr. G.J. Peters; co-promotor: Dr. E. Giovannetti

26. K. Gotink (February 18, 2016)
Tumor cell resistance to antiangiogenic receptor tyrosine kinase inhibitors.
Promotors: Prof. Dr. H.M.W. Verheul; Prof. Dr. G.J. Peters

27. N. Van Der Steen (June 15, 2017; University of Antwerp, Belgium; registered as joint thesis at the VU University, Amsterdam)
The labyrinth of cMET and EGFR in non-small cell lung cancer
Promotors: Prof. Dr. P. Pauwels (Antwerp), Prof. Dr. G.J. Peters, Prof. Dr. P Germompre (Antwerp), Dr. E. Giovannetti

28. G. Li Petri (Double doctorate: February 21, 2020 in Palermo and May 28, 2020 in Amsterdam)
Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole derivatives as anticancer and antibiofilm agents, and preclinical investigation of anti LDH-A compounds against malignant mesothelioma
Double doctorate at: University of Palermo and VU University Amsterdam.
Promotors: Prof. Dr. G.J. Peters, Prof. Dr. P Diana (Palermo); co-promotors: Dr. E. Giovannetti, Prof. Dr. G. Cirrincione (Palermo)

29. B. el Hassouni (June 1, 2021)
Novel therapeutics for pancreatic cancer
Promotors: Prof. Dr. G.J. Peters and Dr. E. Giovannetti

30. C.A. Jaramillo Mantilla (June 21, 2021)
Multidrug resistance mechanisms in cancer: clinical response in patients with MDR and overcoming chemotherapy resistance with phytocannabinoids
Promotor: Prof. Dr. G;J. Peters and Prof. Dr. J. Cloos; co-promotors: Dr. G. Jansen & Dr. R. Stam (Prinses Maxima Centrum)

31. O. Randazzo (Double doctorate: March 15, 2022 in Palermo; June 23, 2022 in Amsterdam).
Design of SF3B1 subunit modulators of the SF3B spliceosome complex
Double Doctorate University of Palermo and VU University Amsterdam)
Promotors: Dr. E. Giovannetti, Prof. Dr. P. Diana; co=promotors: Prof..Dr. G.J. Peters, Dr. S.M. Cascioferro

32. C. Pecoraro (Double doctorate: March 15, 2022 in Palermo; June 23, 2022 in Amsterdam).
Design and synthesis of new 3-amino-1,2,4-triazine compounds as CDK1 inhibitors
Double Doctorate, University of Palermo and VU University Amsterdam
Promotors: Dr. E. Giovannetti and Prof. Dr. P. Diana; co-promotors: Prof. Dr. G.J. Peters and Dr. B. Parrino

Planned:

33. I. Garajova (2023)
Role of MicroRNAs and new targeted treatments in the outcome of gastrointestinal cancers
Promotors: Dr. E. Giovannetti, Prof. Dr. G.J. Peters

34. D. Sarkisjan (2023)
Mechanisms of inhibition of DNA methyltransferase
Promotor: Prof. Dr. G.J. Peters and Dr. E. Giovannetti; co-promotor: Dr. R.J. Honeywell

35. V. Donati (2024)
Promotors: Dr. E. Giovannetti, Dr. D.M. Deng, Prof. Dr. G.J. Peters

36. M. Franczak (2024). Medical University of Gdansk, Poland.
Promotors: Prof. Dr. G.J. Peters and Prof. Dr. RT Smolenski; co-promotors: Dr. E. Giovannetti and Prof.Dr. F. Minutolo.

37. L. Kuipers-de Wilt (2025)
Resistance to proteasome inhibitors and sensitization to TRAIL.
Promotor: Prof. Dr. G.J. Peters, Prof. Dr. F.A.E. Kruyt (Groningen); co-promotor: Dr. G. Jansen

38. A.D. Adema (2025)
DNA damage inducing agents
Promotors: Prof. Dr. G.J. Peters, Prof. Dr. H.M. Verheul; co-promotor: Dr. M.L. Sandvold (Norway)

39. M Rovithi (2025)
Optimiziation of treatment with tyrosine kinase inhibitors
Promotors: Prof. Dr. H.M.W. Verheul, Prof. Dr. G.J. Peters; co-promotor: Dr. H.J. Broxterman

40. F. Terrana (2026)
Novel ragets for imidazo[2,1-b] [1,3,4] thiadiazole derivatives
Promotors: Prof. Dr. E. Giovannetti, Prof. Dr. P. Diana (Palermo, Italy), Prof.Dr. G.J. Peters; co-promotor: Dr. D. Carbone (Palermo, Italy)

Referee of 4 other Ph.D. theses
Thesis advisor of 46 other theses in the Netherlands and 24 abroad
Thesis defense: since 2015 replacement of the rector to chair a thesis defense (frequency once every month/two months)

Publications, presentations

ORCID

orcid.org/0000-0002-5447-2877

Scopus

• 7401522655
  
• 36014019800
  

Prof. Peters has authored/co-authored 464 refereed research papers, 115 invited reviews (refereed), 99 papers in congress proceedings (in refereed journals), 71 in congress book and 20 regular book chapters; and >800 abstracts. Partially in: https://www.ncbi.nlm.nih.gov/pubmed/?term=Peters+GJ

Thomson-Reuter Web of Science evaluation: Citations: 33,917; 21% to first author papers, 52% to senior authored papers, 27% to co-authored papers, with 80 papers >100 and 83 papers with 50-100 citations. The H-factor is 80

Scopus: Total citations: 35,490; h-index 82 (730 papers listed)

Google Scholar: Citations: 52,660 (since 2018: 16364); H-factor 101 (since 2018, 48) and i10index 574 (since 2018: 270).

#28 in the list of top-cited scientists in the field of Pharmacology https://scholar.google.nl/citations?user=kA5Gf9wAAAAJ&hl=en

Mendeley evaluation: Citations 29011 h-index 78, views 161K.

Research gate: Citations; 40,378, reads 158,638 H-index, 89; Research Interest Score 17.927 (higher than 99% of Research gate members).

Prof. Peters is regularly invited at international meetings as invited speaker (> 140), session chairman (>80), post-graduate courses (>10), etc.